journal article·2021-01Open access

Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: pharmacokinetic, pharmacodynamic and scintigraphy study

Pranav Shah, Priya Dubey, Bhavin Vyas, Ankur Kaul, Anil Kumar Mishra, Dimple Chopra, Priya Patel

Abstract

The present study aimed to investigate the brain targeting efficacy of Lamotrigine (LTG) loaded PLGA nanoparticles (LTG-PNPs) upon intranasal administration. LTG-PNPs were fabricated through the emulsification-solvent evaporation technique and evaluated for % Entrapment efficiency, particle size, in-vitro release, surface morphology, crystallinity, ex-vivo permeation & thermal behaviour. Biodistribution, gamma scintigraphy, and pharmacodynamic studies were performed in BALB/c mice, New Zealand rabbits, and Wistar rats respectively. LTG-PNPs exhibited % EE 71%; particle size 170.0 nm; Polydispersity index 0.191; zeta potential −16.60 mV. LTG-PNPs exhibited a biphasic release pattern. Biodistribution and gamma scintigraphy studies proved a greater amount of LTG in the brain following intranasal delivery of LTG-PNPs in comparison to LTG-SOL. Pharmacodynamic studies demonstrated delayed seizure onset time with LTG-PNPs in comparison to LTG-SOL. Intranasal administration of LTG-PNPs provided prolonged release, higher bioavailability, and better brain targeting bypassing the BBB. The developed formulation could be administered as a once-a-day formulation that would reduce the dosing frequency; dose; dose-related side effects; cost of the therapy and would be beneficial in the management of epilepsy as compared to the LTG-SOL. However, the proof of concept generated through these studies needs to be further validated in higher animals and human volunteers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Maliba Pharmacy College, Uka Tarsadia University, Bardoli, India

Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, India

Department of Pharmaceutical Sciences, Punjabi University, Patiala, India

Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, India

References (53)

Show source-provided references
1. Gupta S, Kesarla R, Chotai N, et al. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int. 2017;2017:1–19.10.1155/2017/5984014 ↗
2. 10.2174/156720181766620070811562710.2174/1567201817666200708115627 ↗
3. Singh J, Garg R, Gupta GD. Enhancement of solubility of lamotrigine by solid dispersion and development of orally disintegrating tablets using 32 full factorial design. J Pharm. 2015;2015:828453.
4. Mishra B, Arya N, Tiwari S. Investigation of formulation variables affecting the properties of lamotrigine nanosuspension using fractional factorial design. DARU. 2010;18(1):1–8.
5. 10.1007/s40204-019-0114-910.1007/s40204-019-0114-9 ↗
6. 10.1016/j.ejps.2018.01.02810.1016/j.ejps.2018.01.028 ↗
7. 10.3797/scipharm.1208-1810.3797/scipharm.1208-18 ↗
8. 10.3109/1061186090348339610.3109/10611860903483396 ↗
9. 10.1007/s10856-012-4702-710.1007/s10856-012-4702-7 ↗
10. 10.1016/j.antiviral.2011.09.01210.1016/j.antiviral.2011.09.012 ↗
11. 10.1016/j.ejps.2012.04.01310.1016/j.ejps.2012.04.013 ↗
12. 10.1016/j.actbio.2011.07.02510.1016/j.actbio.2011.07.025 ↗
13. 10.2147/IJN.S1588110.2147/IJN.S15881 ↗
14. 10.1517/17425247.2014.89450410.1517/17425247.2014.894504 ↗
15. 10.1016/j.ijpharm.2015.05.02110.1016/j.ijpharm.2015.05.021 ↗
16. 10.1007/s13346-020-00839-910.1007/s13346-020-00839-9 ↗
17. 10.1016/j.ijpharm.2020.11914810.1016/j.ijpharm.2020.119148 ↗
18. 10.1016/j.jpsychires.2013.10.01110.1016/j.jpsychires.2013.10.011 ↗
19. 10.1517/17425247.2014.94541610.1517/17425247.2014.945416 ↗
20. 10.2147/IJN.S14548810.2147/IJN.S145488 ↗
21. 10.4103/2231-4040.9087610.4103/2231-4040.90876 ↗
22. 10.3390/ijms1503364010.3390/ijms15033640 ↗
23. 10.1007/s13346-019-00622-510.1007/s13346-019-00622-5 ↗
24. 10.1208/s12249-014-0235-310.1208/s12249-014-0235-3 ↗
25. 10.1016/0378-5173(93)90135-310.1016/0378-5173(93)90135-3 ↗
26. 10.1080/03639045.2017.130495710.1080/03639045.2017.1304957 ↗
27. 10.1016/j.jddst.2020.10211210.1016/j.jddst.2020.102112 ↗
28. Shirsat M. Development & validation of a stability-indicating HPLC method for analysis of lamotrigine in bulk drug & formulations. Int J Univ Pharm Bio-Sci. 2013;2:334–353.
29. 10.1186/1477-3155-10-3810.1186/1477-3155-10-38 ↗
30. 10.1016/j.ejps.2012.12.00710.1016/j.ejps.2012.12.007 ↗
31. Keshari P, Sonar Y, Mahajan H. Curcumin loaded TPGS micelles for nose to brain drug delivery: in vitro and in vivo studies. Mater Technol Adv Performance Mater. 2019;34(7):423–432.
32. 10.1016/j.colsurfb.2012.04.02710.1016/j.colsurfb.2012.04.027 ↗
33. 10.1166/jbn.2012.146210.1166/jbn.2012.1462 ↗
34. 10.1016/j.nano.2016.05.00510.1016/j.nano.2016.05.005 ↗
35. 10.1021/cm900172410.1021/cm9001724 ↗
36. 10.1016/j.memsci.2010.11.06510.1016/j.memsci.2010.11.065 ↗
37. 10.2147/IJN.S9854710.2147/IJN.S98547 ↗
38. 10.1016/0883-2897(92)90179-310.1016/0883-2897(92)90179-3 ↗
39. 10.1208/s12249-015-0294-010.1208/s12249-015-0294-0 ↗
40. 10.3109/1061186X.2010.52378710.3109/1061186X.2010.523787 ↗
41. 10.1007/s13346-012-0110-210.1007/s13346-012-0110-2 ↗
42. 10.1016/j.biomaterials.2011.05.07910.1016/j.biomaterials.2011.05.079 ↗
43. 10.1016/j.apsb.2014.02.00210.1016/j.apsb.2014.02.002 ↗
44. 10.3109/1071754090343158610.3109/10717540903431586 ↗
45. 10.1016/j.ijpharm.2013.01.05810.1016/j.ijpharm.2013.01.058 ↗
46. Singhvi G, Singh M. In-vitro drug release characterization models. Int J Pharm Stud Res. 2011;2(1):77–84.
47. 10.1016/j.biomaterials.2005.12.02110.1016/j.biomaterials.2005.12.021 ↗
48. 10.1088/0957-4484/25/48/48510210.1088/0957-4484/25/48/485102 ↗
49. 10.4103/2230-973X.11922710.4103/2230-973X.119227 ↗
50. 10.2147/IJN.S2874510.2147/IJN.S28745 ↗
51. 10.1111/jphp.1307210.1111/jphp.13072 ↗
52. 10.1002/jps.2230710.1002/jps.22307 ↗
53. 10.1016/j.ijpharm.2008.03.02910.1016/j.ijpharm.2008.03.029 ↗